Medical Advocates
Atazanavir (Reyataz)
 
Archived Conference Citations A

3rd IAS Conference
6th Int Workshop on Clinical Pharmacology of HIV Therapy
12th CROI
XV International AIDS Conference
 11th CROI
 9th European Conference on Clinical HIV
 43rd ICAAC
 2nd IAS Conference
 1st European HIV Resistance Workshop
 

  
Atazanavir Conference Citations Main New/Newsworthy Home Page      
Last updated:  June 02, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
3rd IAS Conference on HIV and Pathogenesis
 
  POSTER
 Efficacy of Atazanavir-Based HAART in Patients Switched from a Stable PI or a Boosted PI (PI/r)
Treatment. Planned Week 24 Week Analysis of Phase IIIb 49-Week Multicenter, Open-label,
Randomized Prospective Study: The SWAN Study
 J Gatell, D Salmon-Ceron, A Lazzarin, et al 
 PDF Poster
   
  POSTER
 Atazanavir Use in Pregnancy
 Morris A 
PDF Poster
   
  POSTER
 Pharmacokinetic Effects of Coadministration of Atazanavir and Tenofovir at Steady State
 S. Agarawada, T Eley,  M Child et al
PDF Poster
   
  POSTER
Pharmacokinetic  Interaction between Atazanavir and Omeprazole in Healthy Subjects
 S. Agarawada, K Gray,  T Eley, et al
 PDF Poster
   
  Viral suppression in CSF and genital tract in ritonavir-boosted "atazanavir only" maintenance
therapy (ATARITMO-Study)
 Vernazza P., Daneel S., Schiffer V.
 Abstract
   
  Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with
severe hyperlipidemia
 Moebius U, Lubach-Ruitman M, Castro-Frenzel B., et al
 Abstract
   
  Clinical practice of atazanavir in the real life : Results from a french prospective database of 570
patients
 Pugliese P., Duvivier C., Cuzin L, et al
 Abstract
   
  Hyperbilirubinemia among Patients in the HIV Outpatient Study (HOPS) Receiving Atazanavir
 Ward D., Curtin J., Richardson J., et al
 Abstract
   
  The StARS Study: Once Daily Atazanavir, low-dose Ritonavir and Saquinavir in Subjects with HIV-1
Infection: 24 week efficacy and safety results.
 Colson A., Hellinger J., Cohen C, et al
 Abstract
   
  Variability of atazanavir plasma concentrations in HIV-infected patients: results of a prospective
french cohort
 Guiard-Schmid J.-B., Poirier J.-M., Bonnard P., et al
 Abstract
   
  Non Significant Drug Interaction Between Atazanavir and Proton Pump Inhibitors in Ritonavir
Boosted Regimen
 Guiard-Schmid J.-B., Bonnard P., Poirier J.-M., et al
 Abstract
   
  Longitudinal evaluation of the effect of atazanavir (ATZ) on the fasting parameters of glucose
metabolism
 Guffanti M., Caumo A., Galli L., et al
 Abstract
   
  Interaction between Atazanavir and fosAmprenavir in the treatment of HIV-infected patients
Khanlou H. , Bhatti L., Farthing C., et al
 Abstract
 
A novel, dual protease inhibitor antiretroviral regimen containing atazanavir and fosamprenavir
 Slim J., Najjar M., Fallon S., Smith S.
 Abstract
 
Improvements in serum HDL with the use of atazanavir based regimens-observations from two
clinic practices
 Ganesan A., Crum N., Moise M., et al
 Abstract
 
Immuno-Virological Outcome Of An HAART Regimen Containing T-20, Atazanavir And Tenofovir VS
T-20 Plus Optimized Background In HIV-Positive Subjects With Multiple Treatment Failures
 Bongiovanni M., Cicconi P., Tordato F, et al
 Abstract
 
Effect Of Ritonavir-Boosted Atazanavir (Atv/R) In Experienced HIV-Infected Patients Regarding
Chronic Hepatitis B/C Status.
 Perez-Elias M.J., Gatell J.M., Flores J., et al
 Abstract
 
Lipodystrophy is associated with low rate of treatment failure in HIV-positive patients switched to
boosted Atazanavir (ATV/r).
 Zaccarelli M., Trotta M.P., Zinzi D., et al
 Abstract
 
There is need of drug-class switch to simplify PI-based antiretroviral regimens? Results from two
strategies: atazanavir vs efavirenz-based regimens.
 Zaccarelli M., Liuzzi G., Trotta M.P., et al
 Abstract
 
Dual boosted atazanavir/lopinavir/ritonavir containing regimen in HIV-1 infected pretreated patients :
plasma trough concentration and efficacy results.
 Duvivier C., Peytavin G., Ait-Mohand H., et al
 Abstract
6th International Workshop on Clinical  Pharmacology
of HIV Therapy
  POSTER
Atazanavir (ATV) enhances trough concentrations of Nelfinavir (NFV) and its M8 metabolite
in a treatment regimen without Ritonavir (RTV)
 M Kurowski, et al
PDF Poster
 
  POSTER
 Population pharmacokinetic of Atazanavir in HIV-infected patients
R Lacarelle, et al
PDF Poster
 
  PRESENTATION
 Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: Definition of
therapeutic range
 S. Bonora
Slide Presentation
12th Conference on Retroviruses and
Opportunistic Infections
  Effect of Atazanavir on Serum Cholesterol and Triglyceride Levels in HIV-infected Infants,
Children, and Adolescents- PACTG 1020A
 Rutstein, P Samson, G Aldrovandi, et al
 Abstract

Effects of Switching to Ritonavir-boosted Atazanavir on HIV-infected Patients
Receiving Antiretroviral Therapy with Hyperlipidemia.
 E Martinez, C Azuaje, A Antela,  et al
 Abstract
 
Atazanavir Resistance in a Protease Inhibitor-naïve Patient Treated with Atazanavir/
Ritonavir Associated with Development of High-level Atazanavir Resistance and the
N88S Mutation in Protease
 E Coakley, M Mass, N Parkin
 Abstract
 
POSTER
 Pharmacokinetic (PK) Effect of Omeprazole (OMP) on Atazanavir (ATV) with
Ritonavir (RTV) in Healthy Subjects
 S Agarwala, K Gray, Y Wang, D Grasela.
PDF Poster   Abstract
 
POSTER
 The Influence of Baseline Protease Inhibitor Mutations on the Efficacy of
Ritonavir-Boosted Atazanavir (ATV/r), Atazanavir Plus Saquinavir, and
Lopinavir/Ritonavir (LPV/r) In Patients Who Have Experienced Virologic Failure
on Multiple HAART Regimens
PDF Poster   Abstract
 
POSTER
 AI424067: Improvement in Lipid Profiles After 12 Weeks of Switching to Atazanavir (ATV)
From Boosted or Unboosted Protease Inhibitors (PIs) in Patients With No Previous PI
Virologic Failure and Hyperlipidemia at
M  Sension, B  Grinsztejn, JM  Molina,  et al
 PDF Poster     Abstract      Commentary
 
Pharmacokinetics of Atazanavir/Ritonavir in HIV-infected Infants, Children, and
Adolescents: PACTG 1020A
 J Kiser  R Rutstein , G Aldrovandi , et al
 Abstract
 
Relationship between Low Bone Mass Measurements and Age in HIV-infected Children |
and Adolescents on HAART
 S Mora, V Giacomet, L Cafarelli , et al
 Abstract
 
Trends in Bacteremia in the Pre- and Post-HAART Eras among HIV-infected Children
in the U.S. Perinatal AIDS Collaborative Transmission Study (1986-2004)
 S Nesheim, M Soe, B Kapogiannis, et al
 Abstract
 
Evaluating in vitro the Effect of Amprenavir, Lopinavir, and Atazanavir with or without a
Low Concentration of Ritonavir Using Multiple Adipose Cell Function Endpoints
 M Caron, M Auclair, C Lagathu, et al
 Abstract
 
Effect of Rifampin on Steady–state Pharmacokinetics of Atazanavir and Ritonavir in
Healthy Subjects
 D Burger, S Agarwala, M Child, et al
 Abstract
 
The Clinical Correlations of Trough Plasma Atazanavir Levels in a Cohort of HIV-1-positive
Individuals Receiving HAART
 A  Winston, M Bloch, A Carr, et al
Abstract
 
Synergistic Activity of Atazanavir and Saquinavir on Viruses with Low Saquinavir and High
Atazanavir Resistance
 SL-Binay, L Thibaut, E Dam,  et al
Abstract
 
Use of Bilirubin as a Surrogate Marker of Medication Adherence to Atazanavir-based ART
K Petersen, B Hale, L Jones, et al
 Abstract
XV International AIDS Conference
 
  Maintenance of favorable in vitro metabolic profile of atazanavir when combined with low dose
ritonavir
 MA Noor, R Mulvey, S Wang, et al
 Abstract
 
  Tolerance and Efficacy of Ritonavir-booste Atazanavir in ARV-naive patients
CMM Matillano
 Abstract
 
Improvement in hyperlipidemia following switch of antiretroviral (ARV) therapy to an atazanavir-
based HAART regimen: Experience from the U.S. Atazanavir Early Access Program (EAP)
 G Thal, J Maa, M McManus, et al
 Abstract
 
Atazanavir-based salvage regimens in heavily-pretreated HIV-infected patients
 F Dronda, S Moreno, A Antela, et al
 Abstract
 
Safety profile of atazanavir and correlation with plasma levels
A Rendon, A Barrios, S Rodriguez-Novoa, et al
 Abstract
 
Switching to atazanavir improves metabolic disorders in patients with severe hyperlipidemia
U Moebius, M Lubach-Ruitman, B Castro-Frenzel, et al
 Abstract
 
Atazanavir boosted with ritonavir in protease inhibitor-naive patients
A Wendrow
 Abstract
 
A single centre six-month clinical experience of atazanavir in a Special Access Scheme (SAS)
in Australia
J Sarangapany, M Kelly, S Bridle, J Gold
Abstract
 
Risk of metabolic syndrome (metsyn) among highly-treatment experienced HIV-infected patients –
48 week results from BMS study AI 424045
 U Iloeje, Y Wu, P Cislo, et al
 Abstract
11th Conference on Retroviruses and Opportunistic
Infections
  POWERPOINT POSTER
 Efficacy and Safety of Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs
Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Experienced Virologic Failure on Multiple
HAART Regimens: 48-Week Results From BMS AI424-045
 E DeJesus, B Grinsztejn, C Rodriguez, et al
Poster
 
  POWERPOINT POSTER
 The Effect of Atazanavir vs. Lopinavir/Ritonavir on Insulin-Stimulated Glucose Disposal Rate in
Healthy Subjects
 MA Noor, DM Grasela, RA Parker, et al
Poster
 
Atazanavir Plasma Levels Associated with Efficacy and Safety in Protease Inhibitor-experienced
HIV-infected Patients
 A Barrios, A Rendón, P Ríos, L Martín-Carbonero, et al
Abstract
 
Atazanavir Enhances Saquinavir Hard Gel Concentrations in a Ritonavir-Boosted Once Daily Regimen.
 M Boffito, M Kurowski, G Kruse, et al
 Abstract
 
Pathways to Atazanavir Resistance in Treatment-experienced Patients and Impact of Residue 50
Substitutions
 R Colonno, N Parkin, C McLaren, et al
Abstract

Atazanavir Conference Citations Main New/Newsworthy Home Page      

Archived Atazanavir Conference Citations  A